Epclusa tablets (sofosbuvir and velpatasvir) by Gilead

Description

Epclusa (Sofosbuvir 400mg + Velpatasvir 100mg) is a fixed-dose, pan-genotypic direct-acting antiviral (DAA) combination used for the treatment of chronic hepatitis C virus (HCV) infection across all six major genotypes (1–6), making it a truly universal HCV regimen. Sofosbuvir is a nucleotide analogue NS5B polymerase inhibitor that halts viral RNA replication, while velpatasvir is a pan-genotypic NS5A inhibitor that disrupts viral assembly and replication complex formation. Administered as a single tablet once daily for 12 weeks, it achieves sustained virologic response (SVR) rates exceeding 95% across genotypes, including in patients with compensated cirrhosis, and 12 weeks with ribavirin in decompensated cirrhosis. It is generally very well tolerated, with headache, fatigue, and nausea being the most commonly reported side effects, and is contraindicated with rifampicin and certain other potent inducers of P-glycoprotein and CYP enzymes.